At Sapphire we are constantly working to find ways to ensure we provide our award-winning quality clinical service to patients at more affordable prices.
Today (1st January 2021) we offer the next 2,000 patients further cost savings to be part of our ground-breaking initiative, the UK Medical Cannabis Registry to expand the evidence base of medical cannabis.
Following the success of the Curaleaf Access Scheme launched in June 2020, which offered the first 1,000 patients reduced costs to be involved, we are able to offer further cost savings. Prices start from £100 for an initial consultation, £50 for the first follow up and £45 for quarterly check-ups. Sapphire Patients are never charged a repeat prescription fee and will be able to monitor their treatment outcomes for free using the comprehensive Real World Evidence platform.
Current patients on the Curaleaf Access Scheme can also benefit from this news with reduced appointment prices for follow up consultations.
Sapphire’s Chief Pharmacist Carl Holvey commented to today’s announcement “We’ve helped many patients in 2020 to access treatment with medical cannabis with some life changing results. I am so pleased we are able to expand the Curaleaf Access Scheme to another 2,000 patients from today”
CPASS (Cannabis Patient Advocacy & Support Services) is a cross-sector collaborative initiative providing support for patients and healthcare professional for CBMPs, Basia Zieniewicz Co-Founder and Director commented on this news, “The more patients that are able to access medicinal cannabis on prescription, the closer we will get to demystifying its medicinal value, in turn widening access even further still. Radically reducing cost barriers is key.”
Find out more:-
- Conditions where medical cannabis may be considered
- Our Pricing
- Start your referral via our short online Eligibility Assessment
- Read our Patient Testimonials
Curaleaf Access Scheme
In 2020 Sapphire launched the UK’s first Medical Cannabis Registry via their Real-World Evidence data platform. This allows patients to gain greater insight into how their medical cannabis treatment is affecting them as well as reducing the cost of appointments. This cost saving is given in recognition that patients are contributing to our ground-breaking initiative that will rapidly expand the evidence base for medical cannabis.
